Tizanidine Hydrochloride Capsule
Product Images NDC 72241-043

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tizanidine Hydrochloride (NDC 72241-043). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Modavar Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cont-tizanidine-2mg-150-caps.jpg (Cont Tizanidine 2mg 150 Caps)

Label for Tizanidine Hydrochloride Capsules 2 mg by Modavar Pharmaceuticals LLC. The carton contains 150 capsules. The label includes storage instructions, caution about child-resistant packaging, and a warning that this product is not interchangeable with tizanidine tablets or Zanaflex tablets. Manufactured by Cadila Pharmaceuticals Limited, India, for Modavar Pharmaceuticals LLC, Washington, DC.*

FDA Label Image

Cont-tizanidine-4mg-150-caps.jpg (Cont Tizanidine 4mg 150 Caps)

Label for Tizanidine Hydrochloride Capsules 4 mg by Modavar Pharmaceuticals LLC. The label displays the NDC number 72241-042-07 and indicates a quantity of 150 capsules. It includes caution details, storage instructions, and manufacturing information by Cadila Pharmaceuticals Limited in India. The label also features a barcode and a trademark note for Zanaflex.*

FDA Label Image

Cont-tizanidine-6mg-150-caps.jpg (Cont Tizanidine 6mg 150 Caps)

Label for Tizanidine Hydrochloride Capsules 6 mg by Modavar Pharmaceuticals LLC. The label states the strength as 6 mg per capsule, with a package size of 150 capsules. It includes warnings against interchangeability with other tizanidine products, storage instructions, barcode, manufacturer details (Cadila Pharmaceuticals Limited, India), and prescription-only designation.*

FDA Label Image

Fig1 (Tizanidine Spl Fig 1)

A pharmacokinetic line graph showing plasma tizanidine concentration (ng/mL) over time (hours) post dosing for 2 x 4 mg tizanidine tablets and capsules, each tested with and without food. The graph compares the concentration profiles of tablets and capsules under fed and fasted conditions over 24 hours.*

FDA Label Image

Fig2 (Tizanidine Spl Fig 2)

A line graph depicting the improvement in Ashworth Score over time (hours post-dose) comparing three groups: 16 mg tizanidine, 8 mg tizanidine, and placebo. The vertical axis measures improvement, ranging approximately from -5 to 1, while the horizontal axis spans from 0 to 6 hours post-dose. Error bars indicate variability at each time point.*

FDA Label Image

Fig3 (Tizanidine Spl Fig 3)

A line graph comparing improvement in Ashworth Score over time between Tizanidine (mean dose 28.8 mg) and placebo groups. The x-axis represents study weeks at three time points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation Carried Forward). The y-axis shows improvement scores, with Tizanidine showing greater improvement than placebo at all points, including error bars indicating variability.*

FDA Label Image

Structure (Tizanidine Spl Structure)

Chemical structure diagram of tizanidine hydrochloride, showing its molecular framework including a chlorinated benzene ring, fused heterocyclic ring system, and associated functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.